Alzheimer's care is becoming more measurable at exactly the moment its imaging workflow is becoming more demanding. Disease-modifying therapies require clinicians to confirm pathology, select appropriate patients, and monitor treatment with evidence that can travel across specialists, scanners, and sites.
Microstructure Imaging's FDA-cleared MICSI-PET enters that transition with a focused proposition: use structural MRI to improve neurological PET images while automating standardized amyloid and tau measurements. The value is not a brighter scan alone. It is the possibility of making quantitative PET more consistent in routine practice.
